Eli Lilly and Co. posted results from three studies of edivoxetine. The treatment did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor (SSRI), edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale (MADRS) in three acute randomized placebo-controlled Phase III studies. While the safety and tolerability of edivoxetine was consistent with previous studi...